These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. Andersson EI; Pützer S; Yadav B; Dufva O; Khan S; He L; Sellner L; Schrader A; Crispatzu G; Oleś M; Zhang H; Adnan-Awad S; Lagström S; Bellanger D; Mpindi JP; Eldfors S; Pemovska T; Pietarinen P; Lauhio A; Tomska K; Cuesta-Mateos C; Faber E; Koschmieder S; Brümmendorf TH; Kytölä S; Savolainen ER; Siitonen T; Ellonen P; Kallioniemi O; Wennerberg K; Ding W; Stern MH; Huber W; Anders S; Tang J; Aittokallio T; Zenz T; Herling M; Mustjoki S Leukemia; 2018 Mar; 32(3):774-787. PubMed ID: 28804127 [TBL] [Abstract][Full Text] [Related]
4. BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. Herbaux C; Kornauth C; Poulain S; Chong SJF; Collins MC; Valentin R; Hackett L; Tournilhac O; Lemonnier F; Dupuis J; Daniel A; Tomowiak C; Laribi K; Renaud L; Roos-Weil D; Rossi C; Van Den Neste E; Leyronnas C; Merabet F; Malfuson JV; Tiab M; Ysebaert L; Ng S; Morschhauser F; Staber PB; Davids MS Blood; 2021 Jun; 137(25):3495-3506. PubMed ID: 33598678 [TBL] [Abstract][Full Text] [Related]
5. Network Propagation Predicts Drug Synergy in Cancers. Li H; Li T; Quang D; Guan Y Cancer Res; 2018 Sep; 78(18):5446-5457. PubMed ID: 30054332 [TBL] [Abstract][Full Text] [Related]
6. Integrated Analysis of Drug Sensitivity and Selectivity to Predict Synergistic Drug Combinations and Target Coaddictions in Cancer. Jaiswal A; Yadav B; Wennerberg K; Aittokallio T Methods Mol Biol; 2019; 1888():205-217. PubMed ID: 30519949 [TBL] [Abstract][Full Text] [Related]
7. SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy. Ianevski A; Timonen S; Kononov A; Aittokallio T; Giri AK PLoS Comput Biol; 2020 Feb; 16(2):e1007604. PubMed ID: 32012154 [TBL] [Abstract][Full Text] [Related]
8. Stratification and prediction of drug synergy based on target functional similarity. Yang M; Jaaks P; Dry J; Garnett M; Menden MP; Saez-Rodriguez J NPJ Syst Biol Appl; 2020 Jun; 6(1):16. PubMed ID: 32487991 [TBL] [Abstract][Full Text] [Related]
9. Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma. Berlow NE; Rikhi R; Geltzeiler M; Abraham J; Svalina MN; Davis LE; Wise E; Mancini M; Noujaim J; Mansoor A; Quist MJ; Matlock KL; Goros MW; Hernandez BS; Doung YC; Thway K; Tsukahara T; Nishio J; Huang ET; Airhart S; Bult CJ; Gandour-Edwards R; Maki RG; Jones RL; Michalek JE; Milovancev M; Ghosh S; Pal R; Keller C BMC Cancer; 2019 Jun; 19(1):593. PubMed ID: 31208434 [TBL] [Abstract][Full Text] [Related]
10. Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer. Malyutina A; Majumder MM; Wang W; Pessia A; Heckman CA; Tang J PLoS Comput Biol; 2019 May; 15(5):e1006752. PubMed ID: 31107860 [TBL] [Abstract][Full Text] [Related]
11. In silico drug combination discovery for personalized cancer therapy. Jeon M; Kim S; Park S; Lee H; Kang J BMC Syst Biol; 2018 Mar; 12(Suppl 2):16. PubMed ID: 29560824 [TBL] [Abstract][Full Text] [Related]